Artiva Biotherapeutics reported a net loss of $28.82 million
Artiva Biotherapeutics (ARTV) filed a 10-Q with the SEC on Nov 9, 2026, 4:05 pm ET. Source: the filing on SEC EDGAR.
Quarterly report, 19 new risk factors
- Form
- 10-Q
- Filed
- Importance
- Major
- Accession
- 0001193125-26-453549
- Net loss: $28.82 million for the three months ended Sep 30, 2026
- Diluted EPS: -$2.01 for the three months ended Sep 30, 2026
- Cash and equivalents: $61.23 million at Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
What changed since last quarter
19 new risk factors · 21 removed
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Operating income and margin | −$31.95M | −$26.89M | −19% |
| Net income | −$28.82M | −$25.01M | −15% |
| Operating cash flow | −$28.45M | −$20.36M | −40% |
| Cash | $61.23M | $301.45M | −80% |
New risk factors (19)
- Our strategic review and workforce reduction may not achieve our intended outcomes.* +2 more paragraphs
- We expect to continue to incur significant expenses and additional operating losses for the foreseeable future as we wind down our AlloNK development program, implement our workforce reduction, evaluate strategic alternatives and satisfy our remaining contractual, regulatory and public company obligations. Although… +1 more paragraph
- We may require additional funding to satisfy our obligations or pursue future business plans, and any future product development or commercialization would require substantial additional funding. Such funding may be unavailable or may dilute our stockholders.* +2 more paragraphs
- • developing or re-establishing manufacturing processes to support any future clinical testing of our product candidates.
- In addition, even if our planned trials are successfully completed, the FDA or comparable foreign regulatory authorities may not interpret the results as we do, and more trials could be required before we submit our product candidates for approval. +1 more paragraph
- and 14 more in the filing
Removed risk factors (21)
- We expect to continue to incur significant expenses and additional operating losses for the foreseeable future as we seek to advance our product candidates through preclinical and clinical development, expand our research and development activities, develop new product candidates, complete clinical trials, seek… +1 more paragraph
- We will need to obtain substantial additional funding to complete the development and any commercialization of our current and any future product candidates, which may cause dilution to our stockholders. If we are unable to raise this capital when needed, we may be forced to delay, reduce or eliminate our research… +15 more paragraphs
- There is currently no cell therapy approved in the United States or elsewhere in the world for the treatment of any autoimmune disease, and our research and development activities related to AlloNK for treatment of autoimmune diseases, such as RA, Sjögren's disease, idiopathic inflammatory myopathies, systemic… +4 more paragraphs
- • continuing to develop a manufacturing process to support the clinical testing of our product candidates.
- Current clinical data regarding the efficacy of NK cell therapies against autoimmune diseases are limited, raising uncertainties about the therapeutic benefits of treatments like AlloNK for conditions such as RA, Sjögren's disease, idiopathic inflammatory myopathies, systemic sclerosis, SLE, LN, and other autoimmune… +4 more paragraphs
- and 16 more in the filing